Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia

Advances in the understanding of the molecular basis for acute myeloid leukemia (AML) have generated new potential targets for treatment. Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in AML and mutations in this gene are associated with poor overall survival. AXL pla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Mori, Masamichi, Kaneko, Naoki, Ueno, Yoko, Yamada, Masaki, Tanaka, Ruriko, Saito, Rika, Shimada, Itsuro, Mori, Kenichi, Kuromitsu, Sadao
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2017
Matèries:
Preclinical Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5613053/
https://ncbi.nlm.nih.gov/pubmed/28516360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-017-0470-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars